Mechanism Overview
Target: SGLT2 protein in the kidneys.
Action: Blocks glucose reabsorption.
Result: Increases urinary glucose excretion, leading to lower blood sugar.
SGLT2 INHIBITOR
Insulin-independent: Effective for patients with insulin resistance.
Diabetes & Heart Care
VENFLOGIN-10/25 MG
Empagliflozin Tablets 10/25 mg
Manages T2DM with Cardiovascular Risk Reduction. Empagliflozin protects the heart by helping the body remove excess fluid and sodium, lowering blood pressure and easing the workload on the heart.
Indications
- Type 2 Diabetes Mellitus (T2DM)
- Heart Failure (HF)
- Cardiovascular Risk Reduction
- Chronic Kidney Disease (CKD)
Key Clinical Benefits
- Superior Glycemic Control: Significant reductions in HbA1c and Fasting Plasma Glucose (FPG).
- Cardio-Renal Protection: Reduces the risk of cardiovascular death and hospitalization for heart failure.
- Weight & BP Reduction: Leads to modest weight loss and blood pressure reduction.
- Low Hypoglycemia Risk: Glucose-dependent action minimizes the risk of low blood sugar.
Comprehensive Management (VENFLOGIN-L)
Also available as VENFLOGIN-L 10/5 and VENFLOGIN-L 25/5 (Empagliflozin & Linagliptin), combining an SGLT2 inhibitor and a DPP-4 inhibitor for dual-action control.
